Marc Feiglin

Founding member of a start-up developing a novel platform that enables AI driven small molecule discovery. Excelsior is proud to be a Deerfield portfolio company. Successfully raised $95m as part of a Series A funding round.

Assessed and in-licensed technologies from academic partnerships selected to be built into start-up companies for the Deerfield portfolio. Co-founded and spun-out Deerfield's first platform technology start-up focused on AI-enabled drug discovery space.

Headed cross-functional efforts to develop new corporate capabilities for external equity investment and partnering. Focused on innovative opportunities and potentially disruptive technologies which were core or adjacent to the company's capabilities in life science tools, analytical technologies, diagnostics, and bioproduction.

Led global team responsible for technology scouting, partnership management, and acquisition sourcing for Merck’s Electronics business. Developed partnerships that provided access to early stage technologies in the semiconductor, display, and coatings industries.

Interim leader of team responsible for creating business opportunities for new products, and for existing products within new markets, for Merck's Electronics business.

Scouted for collaborations, partnerships, investments, and other opportunities for Merck Group in Israel. Fostered relationships and collaborations with academics, early-stage start-ups and other multinationals operating within the Israeli high-tech and life sciences ecosystem in Israel.

Invented new approach to droplet based fluidics marketed as eFluidics with 24 awarded patents. Directed all aspects (sales, marketing, R&D, production) of building a new business to develop and commercialize the technology. Managed a global team of internal personnel and contractors spread across 6 countries in US, Europe, and APAC, with responsibility for a multimillion dollar annual budget. Cultivated close partnerships with leading life science research and diagnostic companies to commercialize this technology through negotiation of high-value agreements for product development, licensing, manufacturing and supply.

Identified potential strategic partnership, distribution, in-licensing, and acquisition opportunities to build Tecan’s business in the life sciences. Provided support throughout business related to diligence of technology opportunities; presented a point of view on opportunities through informational memoranda, management presentations and market research. Held leadership positions focused on strategy and technology: Co-chaired corporate patent committee which managed corporate patent portfolio with a focus on maximizing revenue potential; Organized annual Tecan Symposium (www.tecan.com/symposium/) as a valuable tool for market research and marketing in markets ancillary to Tecan's primary space Developed annual symposium series to bring key opinion leaders together to explore merging trends in key markets and application areas of interest to Tecan.

Developed and managed long-term corporate strategy for guiding both organic and acquisitive growth with focus on Life Sciences. Interacted regularly with decision makers at all levels of the company, including the CEO, Board of Directors, and business unit managers, in order to develop and implement plans. Identified and executed on strategic partnership, co-marketing, in-licensing, and acquisition opportunities which increased both revenue and profitability. Successfully expanded customer base into new market segments including establishment of direct sales office in Australia.

Managed marketing group of 8 staff focused on supporting customers in the biotech and pharmaceutical industries. Performed market research, identified business opportunities, developed strategic plans, and negotiated marketing partnerships which enabled Tecan to enter new markets with a positive impact on both sales and profitability. For example, initiated corporate strategy to address forensics market and built Tecan into the number one provider of automated sample preparation systems in this segment.

Increased the revenue potential for Tecan products by transforming commodity products into high-end, value-added “solutions”. Designed and led the development of Tecan’s first application specific products, CrysScreen protein crystallography software and Cellerity fully automated cell growth & maintenance system, which increased revenue potential for these applications over 5 fold. Developed strategic partnerships with life science reagent and consumable companies which provided customers with fully integrated and supported solutions that combined instrumentation with reagents and consumables.

Established business focusing on Process Management informatics solutions for automated laboratory systems. Negotiated strategic partnerships with life science informatics companies that included joint product development of solutions integrating automated hardware systems with data management & analysis software.

Formed first group responsible for designing and developing automated laboratory systems globally throughout Merck's research laboratories. Implemented integrated automation/informatics solutions within both clinical assay development and structural biology departments that increased the quality of assay results.

Founded first department within Merck Research Labs dedicated to automated lead discovery; provided strategic direction as the group became a department of 30 employees to support discovery activities throughout NJ site. Department increased screening throughput 200-fold. Managed annual operating budgets of up to $6m. Research Associate (1998 – 2001) | Research Biochemist (1995 – 1998)

Isolated and characterized two of the enzymes of the Mannitol Cycle in eimeria tenella (a parasite known to infect poultry) and discovered a novel class of low micro molar inhibitors. Built first fully automated high-throughput screening system at Merck. Staff Biochemist (1994 – 1995) | Biologist (1991 – 1994)